+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating Rezpegaldesleukin as a treatment for people aged 12 years and older who have moderate to severe atopic dermatitis. This Phase 3, randomized, double-blind study compares Rezpegaldesleukin to a placebo to assess its effect on this skin condition. The overall participation lasts about 15 months. Participants will receive Rezpegaldesleukin or placebo injections during an induction period every 2 weeks. Afterward, during the maintenance period, Rezpegaldesleukin is given every 4 or 12 weeks, while placebo is given every 4 weeks. There is also an open-label escape phase where dosing frequency is decided by the investigator. Treatments are given by subcutaneous injection. During the study, participants will undergo assessments including the Investigators Global Assessment IGA score, Eczema Area and Severity Index EASI, itch and skin pain scales, sleep quality questionnaires, and asthma and nasal symptom scores. These evaluations happen at baseline, Week 6, and Week 24. Safety is monitored throughout, with adverse events recorded until about Week 56. Participants are followed for approximately 15 months in total.

Age: 12Years +All GendersPhase 3
20 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of enpatoran in adults aged 18 to 75 with active cutaneous manifestations of lupus erythematosus, either with or without systemic disease. This global, multicenter Phase 3 study aims to understand how enpatoran works compared to a placebo in addition to standard care over a 24-week treatment period. The study is sponsored by EMD Serono Research & Development Institute, Inc. and includes participants diagnosed with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, andor Acute Cutaneous Lupus Erythematosus, with or without systemic lupus erythematosus. Participants are randomly assigned to receive either enpatoran tablets or matching placebo tablets taken orally twice daily for 24 weeks while continuing their standard of care treatments. The study intervention is administered as film-coated tablets, and participants are monitored throughout the treatment period. Visits occur every four weeks, with a televisit at Week 2, allowing ongoing assessment of the participants condition and response to treatment. Throughout the study, participants undergo regular evaluations including the Cutaneous Lupus Erythematosus Disease Area and Severity Index CLASI and other measures of lupus activity and symptom changes. Researchers monitor for treatment-emergent adverse events, serious adverse events, and laboratory abnormalities from Day 1 to Week 24. The primary outcome is the percentage of participants achieving a 70% or greater reduction in CLASI-A score at Week 24. Total study participation can last up to 35 weeks, including screening and follow-up assessments.

Age: 18Years - 75YearsAll GendersPhase 3
70 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of bimekizumab compared to a placebo in adults with palmoplantar pustulosis PPP, a condition characterized by pustules on the palms and soles. This Phase 3 study aims to provide important information about this treatment option in participants who have had PPP for at least 24 weeks and meet specific severity criteria. Participants will be randomly assigned to one of two groups one receiving bimekizumab throughout the study and the other receiving a placebo initially, then switching to bimekizumab during the maintenance phase. The treatments are given at scheduled times, and the study includes an open-label extension period to further assess the treatment. During the study, participants will have regular assessments of their skin condition, including the Palmoplantar Pustulosis-Investigator Global Assessment and Palmoplantar Pustulosis Area Severity Index at weeks 8 and 16. Quality of life and pain levels will also be evaluated. Safety is closely monitored through the recording of any adverse events up to approximately 117 weeks. The total time commitment includes initial treatment and an extended safety follow-up period.

Age: 18Years +All GendersPhase 3
91 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety of two drugs, Deucravacitinib and Ustekinumab, in adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic treatments. This study is designed to compare these treatments over an extended period, focusing on cardiovascular health and other safety outcomes. The study is sponsored by Bristol-Myers Squibb and is a Phase 3b4 randomized, open-label trial. Participants are randomly assigned to receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study spans up to 5 years, during which participants will be monitored closely for cardiovascular events and other safety outcomes. Treatment adherence and effects will be regularly assessed throughout this long-term safety study. During the study, participants will undergo various evaluations including monitoring for major cardiovascular events such as heart attacks and strokes, other cardiovascular complications, and laboratory assessments including liver function and lipid panels. Researchers will also track serious adverse events and overall mortality up to 60 days after the last dose. This comprehensive monitoring ensures participant safety and gathers essential data on the long-term effects of the treatments over the studys duration, which lasts until January 2031.

Age: 40Years +All GendersPhase 3
411 locations
O

Actively Recruiting

Researchers are evaluating povorcitinib, an oral tablet, for its pharmacokinetics, safety, and efficacy in adolescents aged 12 to 17 years with moderate to severe hidradenitis suppurativa HS. The study focuses on this condition, characterized by painful skin lesions, and aims to understand how the drug behaves in the body and its impact on disease symptoms over a 54-week treatment period. Participants will receive one of two doses of povorcitinib for 54 weeks in an open-label, non-randomized design. The study includes regular monitoring of drug levels in the blood up to Week 24. The two dose groups will help evaluate differences in treatment effects and safety over the full treatment duration. During the trial, participants will be assessed for adverse events, drug clearance, absorption, and concentration levels. The study will also measure clinical responses such as reduction in abscesses, inflammatory nodules, draining tunnels, skin pain, and quality of life changes using specific scales over 54 weeks. Safety and efficacy data will be collected throughout, with a primary focus on treatment-emergent adverse events and drug pharmacokinetics.

Age: 12Years - 17YearsAll GendersPhase 2
30 locations
O

Actively Recruiting

Researchers are evaluating the real-world effectiveness of nemolizumab Nemluvio4 in treating adults with moderate-to-severe Prurigo Nodularis PN. This observational study aims to measure patient and investigator-reported outcomes over approximately 12 months in routine clinical practice. The study focuses on how patients respond to nemolizumab treatment at 6 months, with ongoing assessments up to a year. Participants who have newly started nemolizumab as determined by their physicians will be observed during their usual care visits. No extra visits, procedures, or lab tests beyond routine care are required. A sub-study in Germany and the UK involves daily patient-reported ratings of itch severity and sleep disturbance for two weeks, collected remotely without clinic visits. During the study, participants will undergo routine evaluations by their doctors, including the Investigator Global Assessment of chronic prurigo stage and questionnaires on itch intensity and sleep quality. These assessments occur at 6 months and continue up to 12 months. This approach allows tracking of treatment effects in real-life settings while minimizing additional burden on participants.

Age: 18Years +All Genders
51 locations
O

Actively Recruiting

Researchers are evaluating the real-world use of nemolizumab for treating moderate-to-severe atopic dermatitis AD in adolescents and adults. This observational study aims to assess the treatments effectiveness through physician evaluations and patient-reported outcomes over six months, providing insight into how the medication performs in everyday clinical practice. Participants receiving nemolizumab as part of their routine care will be observed for about 12 months. Treatment decisions are made by the participants physician before joining the study, with no extra visits or tests beyond usual medical care. A sub-study in Germany and the UK involves daily remote reporting of symptoms such as peak and average itch, sleep disturbance, and pain for the first two weeks. During the study, participants will have regular medical visits as determined by their doctors, with data collected from routine assessments and patient questionnaires. Researchers will measure outcomes like the Investigator Global Assessment and Peak Pruritus Numerical Rating Scale at six months, along with other severity and symptom scores up to 12 months. No additional procedures outside standard care are required, allowing for natural monitoring of treatment effects and safety.

Age: 12Years +All Genders
108 locations
P

Actively Recruiting

This research is a rollover study for participants who have previously taken part in specific Incyte-sponsored clinical trials involving the drug povorcitinib, aimed at treating Hidradenitis Suppurativa HS. The purpose is to continue evaluating the treatments safety and tolerability over an extended period, building on prior studies. Participants must have completed treatment in the original trials without major safety concerns and shown clinical benefits. Participants will continue to receive povorcitinib orally, following the same dosing schedule and options as in their original parent study. This ongoing treatment phase allows researchers to monitor long-term effects and gather extended safety data. The study is designed as a single-group phase 3b trial focused on treatment. Throughout the study, participants will be regularly monitored for treatment-emergent adverse events over approximately three years. Researchers will also assess specific clinical measures at each visit to evaluate treatment impact. Participants are expected to comply with study procedures, including avoiding pregnancy or fathering children as outlined. The total participation duration extends up to about three years, with regular visits to track safety and treatment outcomes.

Age: 18Years +All GendersPhase 3
306 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. This study aims to determine if ENV-294 impacts the severity and affected area of atopic dermatitis and to observe any medical problems participants may experience while taking the drug. Participants will be randomly assigned to receive either ENV-294 or a placebo once daily by mouth for 12 weeks. They will visit the clinic every 2 to 4 weeks for checkups and tests during this period. The study includes keeping a diary of symptoms and medication intake and concludes with a final clinic visit around week 16. During the trial, participants will undergo clinical assessments to evaluate the severity and extent of their skin condition, including scores such as vIGA and EASI. Safety monitoring involves tracking adverse events and laboratory tests. Researchers will also assess pharmacokinetics and patient-reported outcomes. The total participation spans about 16 weeks, covering treatment and follow-up visits.

Age: 18Years - 75YearsAll GendersPhase 2
32 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a drug called ICP-332 in adults with Prurigo Nodularis PN, a skin condition characterized by itchy nodules. This study is a Phase 2 clinical trial designed to compare different doses of ICP-332 against a placebo to better understand its potential benefits and risks for people with PN. Participants are randomly assigned to receive either ICP-332 at doses of 80 mg or 120 mg, or a placebo, with neither the participants nor the researchers knowing which treatment is given to ensure unbiased results. The study involves a 16-week treatment period to assess itch severity, followed by continued assessments up to 40 weeks to monitor skin condition improvements, quality of life, and any side effects. Blood tests will measure how the drug is processed by the body. Throughout the study, participants will be monitored regularly with evaluations of their itch intensity using a numeric scale, skin assessments by doctors, and quality of life questionnaires. Safety will be closely tracked by recording any adverse events. Participants involvement may last up to 40 weeks, including treatment and follow-up periods to gather comprehensive information about ICP-332s impact on Prurigo Nodularis.

Age: 18Years - 75YearsAll GendersPhase 2
43 locations

1-10 of 12

1